Moderna

At Moderna, our colleagues are committed to making a difference in the world beyond our four walls. Each year we launch our global Volunteer Season, a dedicated time when teams around the world step away from day-to-day work to support the communities where we live and work. Now in its seventh year, Volunteer Season has brought together thousands of colleagues to partner with organizations making an impact across the globe.   A few highlights: ✨ Our Basel colleagues joined Werstätte to help transform rescued food into jams, soups and juices that reduce waste and nourish the community. ✨ Cambridge-based volunteers packed more than 950 STEM kits for Science Club for Girls, supporting programming on space exploration, robotics and engineering. ✨ Colleagues in Canada volunteered at a Toronto subsidized housing complex—cleaning, decorating for the holidays, and sharing in a coffee and cookie social with residents. ✨ In Korea, teams partnered with Make-A-Wish to assemble Wish Bears for children living with cancer and other serious illnesses. ✨ Our Princeton colleagues collected donations for the Trenton Area Soup Kitchen. ✨ In Taiwan, colleagues made more than 150 handmade soaps and delivered them to seniors supported by the Eden Social Welfare Foundation.   We are grateful to every colleague who shared their time, energy and heart. You made a positive impact in the places we call home.

November is Lung Cancer Awareness Month — a moment to recognize the strength of those living with the disease and the urgent need for continued innovation in research. For Keith Perry, a dedicated triathlete, a lung cancer diagnosis changed everything. Losing his left lung could have ended his active life but instead, it became the start of a new chapter defined by determination and hope. 🎥 Watch Keith’s full story: https://lnkd.in/e7R2YxYk

Earlier today, we hosted our Analyst Day, which included presentations from management discussing our development and commercial strategy and key business considerations. Members of our executive team sat down to provide a recap of the updates shared. Watch our latest IR Insights video to hear more: https://lnkd.in/erQC4HaA

Today we announced program and financial updates at our Analyst Day event. The updates include mRNA pipeline progress and a three-year plan for strategic growth.   Read more: https://lnkd.in/eu8Uwqem

Today we announced the expansion of our U.S. manufacturing capabilities with the onshoring of Drug Product manufacturing to our existing Moderna Technology Center in Norwood, Massachusetts. Through this strategic onshoring, Moderna will now operate full end-to-end manufacturing for our mRNA medicines in the U.S.   Read more: https://lnkd.in/eAaJHv-k

Earlier today, Moderna reported financial results and provided business updates for the third quarter of 2025. Members of our executive team sat down to provide more insight into our financial performance and upcoming late-stage pipeline milestones. Watch now: https://lnkd.in/eFQp_RXA

Today, we reported financial results and provided business updates for the third quarter of 2025.   Read more: https://lnkd.in/eUs73gW5

We are proud to be recognized on BioSpace's Best Places to Work list of large employers for the fifth-year running! 🎉    This list highlights sought-after employers in life sciences based on community votes and ratings, with a focus on culture, career growth and development opportunities, leadership and innovation.    Learn more: https://lnkd.in/gKuFq2cG

Today we announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, our investigational mRNA-based T-cell engager for participants with relapsed or refractory multiple myeloma (RRMM).    Read more: https://lnkd.in/eSdqXMUM

We’re proud to be named a Science Careers Top Employer for the 11th consecutive year! 🏆   This recognition reflects our incredible teams across the globe who turn bold ideas into real-world impact—those who push the boundaries of what’s possible with mRNA science, technology and innovation. Thank you for the curiosity, passion and commitment you bring every day.   Learn more: https://lnkd.in/eZx9UkYB #SCTopEmployers #BestWorkplaces #ScienceCareers #BiopharmaCareers

Today we announced data regarding two of our investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in Atlanta, GA. Read more: https://lnkd.in/eS3kf5YZ

Today we announced that clinical, safety and translational data from our Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab in checkpoint inhibitor-resistant/refractory (CPI-R/R) melanoma patients will be presented at the 2025 European Society for Medical Oncology (ESMO) Congress, October 17-21, 2025, in Berlin, Germany.   Read more: https://lnkd.in/eJUhVv4s

We were honored to be named Vizient, Inc’s 2025 Pharmaceutical Supplier Partner of the Year at the #VizientAwards. This award reflects our shared commitment to advancing innovation and delivering meaningful impact for patients. Thank you, Vizient, for this recognition and your continued partnership. Read more: https://lnkd.in/g7Mcfnqu

Today we announced that the Moderna Innovation and Technology Centre (MITC) at the Harwell Science and Innovation Campus in Oxfordshire, UK has officially opened. The MITC will now produce British-made mRNA respiratory vaccines for the UK public to support the National Health Service seasonal vaccination programs.    Learn more: https://lnkd.in/e836M7Rv

Today, on #WorldCancerResearchDay, we reflect on the collective progress made in the fight against cancer and the vital work still ahead. Cancer affects millions of people and families worldwide, reminding us of the urgency to continue advancing research and innovation. We are deeply grateful to the scientists, clinicians, patients and advocates whose dedication drives discovery each day. Together, we move closer to a future with more options and more hope for those impacted by cancer.

Today we announced positive preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE® (COVID-19 Vaccine, mRNA), which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. Learn more: https://lnkd.in/ew-JUgCY.

Today we announced that the first mRNA vaccines fully manufactured in Canada are being shipped to Canadian provinces and territories. This milestone advances Canada’s domestic vaccine production capacity and strengthens national health security. Read more: https://lnkd.in/eY-SJsTv.

Today we announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. Learn more: https://lnkd.in/dByZr_s8.

We aspire to be active contributors to the communities where we live and work. Back-to-school season should be about excitement and possibility—not stress over missing supplies. That’s why one of our teams organized a supply drive in partnership with United Way of Tri-County to help students in our local communities start the year confident and prepared. From backpacks to notebooks, crayons to calculators, colleagues came together to provide the essentials kids need to thrive in the classroom.

We are immensely proud of the role we played in the historic achievements of Operation Warp Speed. COVID-19 vaccines helped end the pandemic, re-open economies and save millions of lives. mRNA, the same technology that helped turn the tide of a global pandemic, is now paving the way for breakthroughs in cancer, autoimmune and rare diseases.   To help ensure Americans have clear and accessible information, we will be compiling previously disclosed information here: https://lnkd.in/eMSuchne

Today we announced that five abstracts on our investigational mRNA therapeutics for rare diseases have been accepted for presentation at the 2025 International Congress of Inborn Errors of Metabolism (ICIEM), which will be held September 2-6, 2025, in Kyoto, Japan.   Read more: https://lnkd.in/eVgzHR4J

👋💉 This week, Moderna employees hand-delivered the first shipment of our COVID-19 vaccines to a local pharmacy. We’re grateful to the pharmacies, healthcare professionals and partners who make vaccination possible in our communities.

Today we announced that the U.S. FDA has approved the supplemental Biologics License Applications for the 2025-2026 formulas for Spikevax® and mNEXSPIKE®, targeting the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19.    Read more: https://lnkd.in/eu2amzKc

For Marta Jancz, joining Moderna opened the door to build smarter systems and drive real change. From transforming field medical insights into strategy to piloting AI tools, she’s fueled by the chance to improve how things work.     💡 “I didn’t want to just follow a job description—I wanted to shape it,” Marta shares.     Read more about Marta’s journey: https://lnkd.in/eRXXSvKz

Today we announced that Health Canada has authorized our updated COVID-19 mRNA vaccine, Spikevax®, targeting the SARS-CoV-2 LP.8.1 variant, for individuals aged six months and older. We are on track to deliver the updated vaccine in time for the 2025-2026 vaccination season.   Read more: https://lnkd.in/eNmYKf_n

Join us in welcoming our fall Co-op cohort! These students are joining teams across Technical Development, Research, Development and Digital functions, representing a wide range of colleges and universities.     Their journey began with a full day of onboarding, featuring insights from executive speakers, a panel of former interns and Co-ops and networking opportunities to help them build community from day one.     At Moderna, students gain hands-on experience at the forefront of science and technology, while participating in leadership speaker series and opportunities to grow their personal and professional networks.     Welcome to Moderna!

What constitutes a protein, and how exactly does a protein come together?    Amino acids work together to form intricate chains that fold into functional proteins, each playing their specific role in the body. Watch this video to uncover how it all happens. For a deeper dive, head to Module 1 on our free 'mRNAs as Medicines' course on Coursera to learn more. https://lnkd.in/dCtbvvDD

Our interns recently spent a morning giving back along the Charles River Esplanade, bringing enthusiasm and teamwork to a day of service in the sun.    From refreshing green spaces to making walkways shine, their dedication was on full display. Whether in the lab, in the community or around the world, we believe in using our time and energy to make a lasting impact.    Thank you to our incredible interns for making a difference! 

Earlier today, Moderna reported financial results and provided business updates for the second quarter of 2025. Members of our executive team sat down to provide more insight into our financial performance and upcoming late-stage pipeline milestones. Watch now: https://lnkd.in/enWMWtsT

Today, we reported financial results and provided business updates for the second quarter of 2025. Read more: https://lnkd.in/eA5bnSRQ

Today we announced that the UK Court of Appeal has upheld the validity of our EP’949 patent. Read more: https://lnkd.in/ezPPMm6s

Today we announced that the European Commission has granted marketing authorization for the updated formulation of our COVID-19 vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older.    This marketing authorization follows the Positive Opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use.   Read more: https://lnkd.in/e2ZDqTS5

Today we announced that three abstracts on our investigational mRNA therapeutics have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) Congress, which will be held October 17-21, 2025, in Berlin, Germany. Read more: https://lnkd.in/egqK_X5h

Today we announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization for an updated formulation of the COVID-19 vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older.   Read more: https://lnkd.in/ejxV-jqJ

For Jagjit Ludu, joining Moderna meant the chance to think differently and connect science to people in new ways. From launching clinician-focused docu-series to building AI-powered tools for bite-sized learning, he’s reshaping how Medical Affairs engages and informs. 💡 “Being a changemaker means hearing ‘no’ and persisting,” Jagjit shares. His work is proof that creativity and science can move together—and make an impact. Read more about Jagjit’s journey: https://lnkd.in/eex_9nSs

We are proud to have earned a top score on Disability:IN’s 2025 Disability Index and to be recognized for #DisabilityInclusion for the 4th year in a row! 🏆    Leading with belonging is essential to helping our people thrive. Thank you Disability:IN for this recognition and for your ongoing leadership in advancing disability inclusion across the business community. 

Today we announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for Spikevax®, our COVID-19 vaccine, in children 6 months through 11 years of age who are at increased risk for COVID-19 disease. Our COVID-19 vaccine, mRNA-1273, was previously available for pediatric populations under Emergency Use Authorization.    Read more: https://lnkd.in/dxEgzjY9

Congratulations to our Chief Legal Officer, Shannon Thyme Klinger, on this well-deserved recognition. Shannon’s bold leadership and deep commitment to patients continues to inspire our teams and shape the future of medicine across Moderna and our industry.

Today we announced positive results from a Phase 3 efficacy study evaluating the relative vaccine efficacy against influenza illness of mRNA-1010, our seasonal influenza vaccine candidate, compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older.   Read more: https://lnkd.in/e5KneRqt

CMV Awareness Month in June highlights the impact of congenital cytomegalovirus (CMV), the most common congenital infection worldwide, affecting 1 in 200 newborns in the US and up to 12 in 200 in developing countries. As part of Moderna’s #StimulatingtheScience initiative, we’re recognizing peer-reviewed studies that are shaping the future of CMV awareness, surveillance and care.   The second article we’re proud to highlight this month is by Dr. Chelsea Lutz, PhD, MPH, CPH, et al., and is titled, “Updated National and State-Specific Prevalence of Congenital Cytomegalovirus Infection, United States, 2018–2022” This study presents the most recent national and state-specific estimates of congenital CMV (cCMV) prevalence in the U.S., adjusted for maternal age and demographic differences across populations. The findings reveal clear health disparities in cCMV burden by race, ethnicity, maternal age and geography—insights that are critical for informing more targeted and equitable public health strategies, screening programs and future vaccine efforts.   We thank the authors for their important contributions to the field that support efforts to reduce the burden of cCMV nationwide. Read the paper: https://lnkd.in/eC4-5-RN

mRNA medicines could be transformative. They can be personalized for a single patient, tailored for a rare disease or developed at scale for millions, as seen with the COVID-19 vaccine.    But how are these medicines made? Watch this video to explore the innovative process that starts with a DNA template and leads to groundbreaking medical advancements. You can also head to Module 1 on our free 'mRNAs as Medicines' course on Coursera to learn more. https://lnkd.in/dCtbvvDD  

June is CMV Awareness Month—a time dedicated to raising awareness about cytomegalovirus (CMV), the leading infectious cause of birth defects in the United States. As part of this effort, our #StimulatingtheScience initiative recognizes and celebrates important, peer-reviewed research that advances our understanding of CMV and supports efforts to improve prevention, diagnosis and care.   The first study we are recognizing for our initiative is by Dr. Mallory Baker, et al., and is titled, “Timing of Congenital Cytomegalovirus Diagnosis and Missed Opportunities”. This study sheds light on how delayed diagnoses of congenital CMV (cCMV) can result in missed opportunities for early treatment, monitoring and intervention. Nearly half of the infants in the cohort were not diagnosed until after 3 weeks of age, with some diagnoses occurring well after the onset of sensorineural hearing loss. The findings emphasize the importance of early screening strategies—including universal and expanded targeted approaches—to prevent diagnostic delays and improve developmental outcomes.   We thank Dr. Baker and her colleagues for their meaningful contribution to the field and for helping shape the case for improved cCMV detection and care pathways. Read the study: https://lnkd.in/eA3Vqrvx

Welcome to our 2025 Summer Intern Cohort! 🎉   We’re excited to welcome more than 30 outstanding undergraduate and graduate students from 18 colleges and universities. Contributing across the organization, they represent the next generation of innovators in science, technology and business.   This summer, they’ll work alongside teams throughout Moderna to learn, grow and help advance our mission to deliver the greatest possible impact to people through mRNA medicines.   We can’t wait to see what they’ll accomplish. Welcome to the team!

This past weekend, our colleagues marched together in both Boston and Warsaw to support one another and celebrate community, connection and the spirit of Pride. Thank you to the members of the Moderna RaiNbow Alliance, our LGBTQ+ Employee Resource Group, for your leadership and continued support in creating a workplace where everyone can be themselves. #Pride Month is a moment to reflect, celebrate progress and continue working toward a world where everyone can live authentically and feel a true sense of belonging. 🌈

There’s more to cytomegalovirus than most people realize.     While #CMV is often associated with hearing loss, the impact can go far beyond that. In this short video, Michelle shares how her son’s developmental milestones—like crawling and feeding himself—have required extra support.     CMV is a common virus, but for babies born with it, the challenges can be lifelong and wide-ranging.      This #CMVAwarenessMonth, take a minute to learn about CMV ⬇   https://lnkd.in/diR9y_Sx

We announced today that the U.S. FDA has approved mRESVIA®, our respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 18–59 years of age who are at increased risk for disease. This approval expands the previous indication of mRESVIA, which was approved in May 2024 for adults aged 60 years and older.   Read more: https://lnkd.in/eCv4RTrg

Cytomegalovirus (#CMV) is more common than you might think—yet many parents hear about it for the first time only after diagnosis. In this short video, Michelle shares how she learned about CMV after her newborn son failed a hearing test. Most people haven’t heard of CMV, but it’s the leading infectious cause of birth defects in the U.S., including hearing loss, and affects 1 in every 200 babies. This #CMVAwarenessMonth, take a minute to learn about CMV: https://lnkd.in/diR9y_Sx

Nucleotides are the basic building blocks of nucleic acids (RNA and DNA), but how do they come together to form mRNA?    Discover the simple yet powerful elements that make up mRNA and enable it to carry life’s essential instructions by heading to our free Coursera course, mRNAs as Medicines. https://lnkd.in/dCtbvvDD

mNEXSPIKE® (COVID-19 vaccine, mRNA) is now approved in the U.S., marking our third approved product. We are proud of our platform’s continued impact, and our relentless commitment to excellence. Read more from our CEO Stéphane Bancel about this approval, and what’s next: https://lnkd.in/eNyCs9vg

We announced today that the U.S. FDA has approved mNEXSPIKE®, a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.   Learn more: https://lnkd.in/esw_CZEy

Today we announced an update on our investigational pandemic influenza program. Learn more: https://lnkd.in/ekEJnH9v.

Today we announced that we have submitted an application to the U.S. Food and Drug Administration for review of our Spikevax 2025-2026 formula, a COVID-19 vaccine targeting the SARS-CoV-2 variant LP.8.1. Read more: https://lnkd.in/esTqSGJn.

Today we announced an update on our BLA submission for our combination vaccine against influenza and COVID-19. Read more: https://lnkd.in/eWYmEZ6z

Today, on #ClinicalTrialsDay, we pause to thank the people who make progress in medicine possible.    To the participants who lend their time, trust and courage.  To the researchers who push the boundaries of science.  To the coordinators, nurses and support staff who keep it all running.    Your contributions help turn scientific discovery into real-world impact for patients.    Thank you for everything you do.

START has officially dosed the first U.S. participant in Moderna’s Phase 1 clinical trial of mRNA-4106, a novel pan-tumor antigen therapy candidate for advanced solid tumors. https://lnkd.in/eN_w8Y6F This first-in-human study represents more than just a scientific milestone—it’s a demonstration of what’s possible when innovation meets access. The trial was initiated at START San Antonio, led by Dr. Amita Patnaik, MD, FRCPC, who shared, “mRNA represents a bold new frontier in cancer immunotherapy, and we’re proud to provide our patients access to this innovative treatment as part of a first-in-human trial.” Our CEO, Nick Slack, MBE, emphasized the impact of this moment: “This milestone reflects the core of who we are at START—accelerating the next generation of cancer therapies by bringing them directly to patients in the communities where they live.” We’re proud to partner with Moderna and contribute to advancing mRNA-based innovation in oncology. Learn more about the study: https://lnkd.in/eQE7-WJG #oncologyresearch #mRNA #clinicaltrials #oncology

Skin cancer is the most common cancer in the U.S.—but it's also one of the most preventable. Most skin cancers, including melanoma—the deadliest form—are caused by UV exposure from the sun, tanning beds or sunlamps.    This Melanoma and Skin Cancer Awareness Month, here are 3 things to remember to help protect yourself and your loved ones:    ☀️ Know your risk – Anyone can get skin cancer, but certain factors raise the risk.  🧴 Reduce your exposure – Think sunscreen, shade and protective clothing.  🕵️♀️ Monitor your skin – Melanoma is easier to treat the earlier it’s diagnosed.    Prevention is powerful. This summer, protect your skin and share the facts.    Learn more: https://lnkd.in/e5_z7APx

Earlier today, we reported financial results and provided business updates for the first quarter of 2025.    For the latest episode of our #IRInsights series, members of our executive team sat down to provide more insight into our financial performance and upcoming late-stage pipeline milestones.    Watch the full video here: https://lnkd.in/ePBpt7QG

Today, we reported financial results and provided business updates for the first quarter of 2025.   Read more: https://lnkd.in/eqvEYTWw

At Moderna, we recognize that human and planetary health are interconnected—and that we have a responsibility to grow in a way that protects the planet and minimizes our environmental impact.    To celebrate Earth Day, colleagues from our Cambridge, Massachusetts, office rolled up their sleeves to clean and care for the tree wells in the neighborhood surrounding our headquarters, contributing to a healthier environment in the community we call home.    This is just one way we’re putting our values into action. We recently achieved validation of our near-term and net-zero science-based targets by the Science Based Targets initiative (SBTi)—a major milestone in our journey to reach net-zero greenhouse gas emissions across our value chain by 2045.    Learn more about how we’re building a more sustainable future: https://lnkd.in/eR-A3EsK

We’re excited to announce that the Moderna Innovation and Technology Centre (MITC), located in Harwell, Oxfordshire, has been granted a Manufacturer’s/Importer’s Authorization (MIA) by the Medicines and Healthcare products Regulatory Agency (MHRA).   This follows a successful inspection confirming the facility’s compliance with the principles and guidelines of Good Manufacturing Practice (GMP), which enables the MITC to become fully operational and on track towards producing mRNA vaccines in the UK in 2025. With the manufacturer’s license now in place, we can move forward with commercial mRNA vaccine manufacture, which will be subject to the standard regulatory review processes with the MHRA.   Just two years since breaking ground at the site, we’re proud to look ahead to delivering British-made vaccines to the UK public—supporting the NHS, enhancing the country’s pandemic preparedness and contributing to the UK’s growth mission.   #ModernaUK

🔬⚛️ On #WorldQuantumDay, we’re taking a closer look at how this evolving technology might change drug discovery. Wade Davis, SVP, Digital for Business at Moderna, weighs in on the potential—and the challenges ahead. Read more: https://lnkd.in/gtynsMA3 

The future of #STEM starts in the classroom. We're proud to support the Massachusetts Science & Engineering Fair and honor educators who go above and beyond to make hands-on #science and discovery possible for students across Massachusetts.

We’re proud to be named a LinkedIn Top Company for the second year in a row!   This recognition reflects the bold thinking, collaboration and purpose our teams bring every day. Our people, who care deeply for our patients, communities and each other, are the driving force behind our science and our culture.   To our colleagues: thank you for making this a remarkable place to work. 🧬💡👩🏽🔬

We announced today that Moderna will deliver twelve scientific presentations at the ESCMID Global Congress in Vienna, Austria, April 11–15, 2025. This includes three oral presentations, one e-poster presentation, and eight poster presentations, highlighting the breadth of our research in respiratory and emerging infectious diseases. #ESCMIDGlobal2025    Learn more: https://lnkd.in/ecTPJreS

Have you ever wondered what happens when you're infected with a virus like the #flu, or SARS-CoV-2? How does it multiply and spread in your body?    Watch this video to learn how your own cellular machinery fuels the spread of viruses.    You can also head to Module 1 on our free 'mRNAs as Medicines' Coursera course to find out more about how viruses spread: https://lnkd.in/dCtbvvDD #mRNA101

We announced today that the Australian Therapeutic Goods Administration has granted approval for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to prevent lower respiratory tract disease caused by RSV infection in adults aged 60 years and older.   Read more: https://lnkd.in/eAi8r5ZP

It was a pleasure to welcome Laurent Muschel and his team from the European Commission’s Health Emergency Preparedness and Response Authority (HERA) to Madrid.   We were proud to showcase how Moderna’s manufacturing capabilities — including our partnership with Rovi and our Center of Analytical Excellence — contribute to Europe’s health security.   We have a full end-to-end manufacturing footprint in the European Union, one of our largest outside of the U.S. With a global supply chain, strong R&D focus, and pandemic-hardened contingency plans, we’re prepared to respond to future health threats efficiently and at scale.   #mRNA #HealthSecurity #HERA #PublicHealth #Manufacturing #Madrid

For Monika Kowalska, joining Moderna meant the chance to build something new and make an impact. From ensuring the accuracy of safety data to shaping a growing team, she’s driven by the opportunity to improve how things work.    💡 “Being a changemaker means seeing gaps, asking ‘why,’ reflecting, and figuring out how to make things better,” Monika shares.    Read more about Monika’s journey: https://lnkd.in/eSdbi-gA

This Women’s History Month, our Women’s ERG, WISDM, hosted a career panel featuring senior leaders in our research organization, including Rose Loughlin, EVP, Research, to discuss perseverance, discovery and success from the bench to the office. WISDM plays a key role in fostering career development and leadership opportunities for women at Moderna, creating spaces for learning, connection and growth. Join us in celebrating the women shaping the future of science and beyond. Tag a mentor or ally who has made a difference in your career! #WomensHistoryMonth #WomenInSTEM

In 2024, we navigated a rapidly evolving healthcare ecosystem while making significant progress across our pipeline. With two approved mRNA medicines, a deep late-stage portfolio and cutting-edge digital innovations, we remain focused on delivering impact for patients. Through it all, our people—driven by a shared commitment to science and to each other—continued to push the boundaries of what’s possible.     Read our 2024 Annual Report to learn more: https://lnkd.in/eNASj4Vh